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Abstract
Background/Aim. Ischemic heart disease is mostly a con-
sequence of atherosclerosis. Besides the inflammation, the
Fas/Fas ligand (FasL)/caspase death pathway is docu-
mented to be activated in atherosclerotic lesions. The aim of
this study was to compare the values of soluble forms of
Fas and FasL in patients with different presentations of
coronary disease and to correlate Fas/FasL with risk fac-
tors. Methods. We studied 30 patients with chronic stable
angina pectoris (SAP), 27 with non-stable angina pectoris
(NSAP), and 39 with acute ST-elevation myocardial infarc-
tion (STEMI) and 27 age-matched healthy volunteers (the
control group). Serum Fas/APO1 and FasL concentrations
were determined using a commercially available enzyme-
linked immunoassays (ELISA). Results. Fas/APO-1 levels
in the STEMI patients (6.981 ± 2.689 ng/mL) were signifi-
cantly higher than Fas levels in the controls (5.092 ± 1.252
ng/mL, p < 0.01), but not significantly higher than Fas val-
ues in the SAP (5.952 ± 2.069 ng/mL) and the USAP pa-
tients (5.627±2.270 ng/ml). Levels of FasL did not show
any significant difference among the studied groups. In the
SAP patients Fas/APO1 showed a significant positive cor-
relation with high sensitivity C-reactive protein (hsCRP)
(p < 0.05) and a negative correlation with high-density lipo-
protein cholesterol (HDL-C) (p < 0.05), while FasL showed
a significant positive correlation with low-density lipopro-
tein cholesterol (LDL-C) (p < 0.05). Fas levels between the
patients having cholesterol within normal range and those
whose cholesterol was above the normal range showed a
significant difference (p < 0.05) only in the NSAP patients.
Fas and FasL levels between the patients with hsCRP lower
than 3.0 mg/L and those with hsCRP higher than 3.0 mg/L
of the SAP group showed a significant differences
(p < 0.001,  p < 0.05,  respectively).  Strong correlation be-
tween Fas concentration and diabetes mellitus (p < 0.05)
and FasL concentrations and both cholesterol (p < 0.01)
and triglycerides (p < 0.01) in the NSAP patients was ob-
served. The patients in the SAP group showed no strong
correlation between Fas and FasL concentration and risk
factors.  Conclusions.  The obtained results showed that
apoptotic process is dysregulated in the patients with ische-
mic heart disease. Interdependence between Fas and FasL
and inflammatory and lipid markers as well as with cardio-
vascular risk factors was established.
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Apstrakt
Uvod/Cilj. Ishemijska bolest srca je najčešće posledica
ateroskleroze. Pored inflamacije, u aterogenezi je dokazana
aktivnost spoljašnjeg puta apoptoze (Fas/FasL/kaspaza
puta). Cilj ove studije bio je poređenje nivoa Fas i FasL
kod bolesnika sa različitom prezentacijom koronarne bole-
sti i korelisanje Fas/FasL s faktorima rizika. Metode. Is-
pitano je 30 bolesnika sa stabilnom anginom pektoris
(SAP), 27 sa nestabilnom anginom pektoris (NSAP), 39 sa
akutnim infarktom miokarda (AIM) i 27 zdravih osoba.
Koncentracije Fas i FasL u serumu određivane su komer-
cijalnim ELISA testovima. Rezultati. Koncentracije Fas
kod bolesnika sa AIM (6,981 ± 2,689 ng/mL) bile su stati-
stički značajno više od koncentracija Fas ispitanika kon-
trolne grupe (5,092 ± 1,252 ng/mL, p < 0,01) i statistički
neznačajno više od Fas nivoa u SAP i NSAP grupi. Kod
ispitivanih grupa nije bilo statistički značajne razlike u vre-
dnostima FasL. Kod bolesnika sa SAP postojala je značaj-
na pozitivna korelacija Fas i visoko senzitivnog C-Strana 538 VOJNOSANITETSKI PREGLED Volumen 67, Broj 7
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reaktivnog proteina (hsCRP) (p < 0,05), negativna korela-
cija Fas i lipoproteina velike gustine (HDL-C) (p < 0,05) i
pozitivna korelacija FasL sa lipoproteinima niske gustine
(LDL-C) (p < 0,05). Koncentracije Fas  kod  bolesnika sa
normalnim i povišenim vrednostima holesterola značajno
su se razlikovale (p < 0,05) kod grupe NSAP. Vrednosti
Fas i FasL kod bolesnika sa vrednostima hsCRP ispod 3,0
mg/L i onih sa hsCRP iznad 3,0 mg/L značajno su se raz-
likovale u grupi SAP (p < 0,001, odnosno p < 0,05). Pos-
tojala je jaka korelacija koncentracije Fas i dijabetesa
(p  <  0,05) i koncentracije FasL i holesterola (p < 0,01)  i
triglicerida (p < 0,01) u grupi NSAP. U grupi SAP nije po-
stojala značajna korelacija koncentracija Fas i FasL i fakto-
ra rizika. Zaključak. U ishemijskoj bolesti srca postoji
međuzavisnost Fas/FasL i inflamatornih i lipidnih marke-
ra, kao i faktora rizika od koronarne bolesti.
Ključne reči:
miokard, ishemija; fas ligand protein; antigeni, CD95;
zapaljenje, medijatori; arterioskleroza; faktori rizika;
lipoproteini, LDL holesterol; lipoproteini, HDL
holesterol.
Introduction
Ishemic heart disease is mostly a consequence of athero-
sclerosis. Atherosclerosis represents a chronic inflammatory
state which leads to the evolution of an uncomplicated ather-
omatous plaque into complex and vulnerable atheroma. A
flared plaque inflammation is considered to be the source of
intimal erosion and rupture and therefore of acute ischemia 
1.
Besides the inflammation, the Fas/Fas ligand (FasL)/caspase
death pathway, involved in extrinsic apoptotic pathway, is
documented to be activated in atherosclerotic lesions. Dys-
regulation of apoptosis within a vessel wall and upregulation
of the Fas/FasL system contribute to the development of ath-
erosclerosis 
2. The effects of apoptosis during atherogenesis
depend on the stage of the plaque, localization and the cell
types involved 
3. Both macrophages and smooth muscle cells
as well as endothelial and blood borne cells, undergo apoptosis
in atherosclerotic plaque 
4.
The Fas ligand (FasL; CD95 or APO-1 ligand)
 is a cyto-
kine that mediates apoptosis by binding to its receptor,
 Fas
(CD95 or APO-1), leading to the activation of executor
caspases 
5. Fas is expressed almost ubiquitously in a variety of
cells, including cardiomyocytes, whereas FasL is mainly ex-
pressed in
  natural killer cells, activated T cells and macro-
phages as well as in immune-privileged tissues of the eye and
testes 
6. Proteins secreted by cells implicated in atherosclerotic
lesions,
 including soluble Fas (sFas) and soluble Fas ligand
(sFasL),
 circulate in small, but detectable amounts.
Soluble Fas is
 generated by alternative messenger RNA
splicing capable of encoding
 a soluble Fas molecule lacking
the transmembrane domain 
7, while
 sFasL is released in the se-
rum from membrane-bound FasL processed
 by a metallopro-
teinase 
8. It has been demonstrated that Fas and
 FasL are ex-
pressed in atherosclerotic lesions and the Fas/FasL
 system is
related to the apoptotic and inflammatory responses
 present in
atherosclerotic plaques 
9. Measurement of circulating markers
of inflammation may provide some insight into this process.
The first aim of this study was to compare the values
of soluble forms of Fas and FasL in patients with different
presentations of coronary disease and to correlate Fas/FasL
with risk factors. The second aim of this study was to
evaluate the diagnostic values of soluble forms of Fas and
FasL in patients with stable angina pectoris (SAP), non-
stable angina pectoris (NSAP) and acute myocardial in-
farction (AMI).
Methods
The study involved 96 patients with angina chest pain
admitted to the Institute for Cardiovascular and Rheumathic
Diseases “Niška Banja”. Among them, 30 patients (11 females
and 19 males, aged 60.17 ± 11.78 years) had chronic SAP, 27
(15 females and 12 males aged 68.33 ± 8.75 years) had NSAP,
and 39 (12 females and 27 males, aged 64.87 ± 9.03 years) had
acute ST-elevation myocardial infarction (STEMI). Further-
more SAP was defined as a typical exertional chest pain last-
ing from 1 to 15 minutes relieved by glyceryl trinitrate, elec-
trocardiogram (ECG) changes (depression or elevation of ST-
segment) in angina attack or with positive responses to exer-
cise ECG and/or positive stress echocardiography testing.
None of the patients from this group had a previous myocar-
dial infarction in their history, as well as a cardiomyopathy,
malignant arrhythmias or cardiac valve disease. All NSAP pa-
tients had angina chest pain at rest within the past 48 hours
(class IIIB) 
10, typical changes in ECG (ST-segment changes,
T-wave changes), negative cardiac enzymes and negative tro-
ponin I. Diagnosis of AMI was based on the ischemic symp-
toms (chest pain persisting longer than 30 minutes) and typical
changes on the ECG at the admission and elevated troponin I
levels. All of these patients had STEMI, which was defined as
significant ST-elevation according to the current Guidelines of
the European Society of Cardiology (new ST-segment eleva-
tion at J point with the cut-off points ≥ 0.2 mV in V1 through
V3 and > 0.1 mV in other leads) 
11.
All patients gave the data about age, sex, risk factors:
hypertension, diabetes mellitus, smoking, obesity (an obese
person is every person with body mass index higher than 25
kg/m
2), family history (family history are data about fathers’
or mothers’ appearance of AIM before 60 years of age),
physical inactivity (physical inactive persons are ones who
have way of life without any physical activity in their free
time), cholesterol and triacylglycerol levels, and current
therapy just after admission.
Venous blood samples from patients were taken within
24 hours after admission and standard analyses were perfo-
med on the same day. Sera for Fas and FasL were collected
and stored in aliquots at -20 ºC until analysis.
We also tested 27 healthy volunteers (the control group).
The controls were recruited from the Department for Blood
Transfusion from blood bank donors. The volunteers did not
have any history of hypertension, diabetes or ischemic heartVolumen 67, Broj 7 VOJNOSANITETSKI PREGLED Strana 539
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disease. The patients and volunteers gave written infomed con-
sent before the study entry and the study was approved by the
local Ethic Committee. All the patients were followed up for 1
year. Major clinical events during the follow-up were class III
NSAP, non-fatal myocardial infarction and cardiac death.
Serum Fas/APO1 concentrations were determined us-
ing a commercially available immunoassay (ELISA kit,
BioSource, Nivelles, Belgium) with sensitivity < 20 pg/mL.
Serum FasL concentrations were determined using a
commercially available immunoassay (ELISA kit, Bio-
Source, Nivelles, Belgium) with sensitivity < 0.1 pg/mL.
All other biochemical markers were estimated by an
analyzer Olympus AU 400 (Olympus, Tokyo, Japan) and
troponin I concentration by AxSYM analyzer (Abbott Labo-
ratories, Abbott Park, IL, USA).
Statistical analysis was performed to identify the differ-
ences in serum concentrations of apoptotic markers, as well as
to correlate their levels with standard biochemical markers and
risk factors. The obtained data were tested out using analysis
of descriptive (avarage, standard deviation) and analytical
(Dunnett’ test-for multiple comparisons; Student’s non-paired
t test) statistics. Linear regression analysis was used to assess
the relationships between the studied apoptotic markers and
risk factors. Statistical analysis was performed with the Statis-
tical Package for the Social Sciences (SPSS) 15.0 computer
program (SPCC Inc, Chicago, IL, USA).
Results
Baseline characteristics of patients and coronary risk
factors are shown in Table 1. The NSAP patients had the
highest prevalence of physical inactivity (100%) and hyper-
tension (81.48%), higher than the SAP and STEMI patients.
The SAP patients had a higher prevalence of smoking habits
(50%) and the most STEMI patients had familiar history of
coronary heart disease (51.28%).
Serum concentrations of apoptotic markers Fas and
FasL are given in Figures 1 and 2. Fas levels in the STEMI
Table 1
Baseline characteristics and coronary risk factors in patients with ischemic heart disease
Parameters STEMI patients
(n = 39)
NSAP patients
(n = 27)
SAP patients
(n = 30)
Controls
(n = 27)
Age (years), ґ ± SD 64.87 ± 9.03
* 68.33 ± 8.75
‡ 60.17 ± 11.78 58.52 ± 5.60
Sex (male/female), n 27/12 12/15 19/11 12/15
Coronary risk factors
hypertension (%) 76.62
† 81.48
‡ 66.67
§ 0
diabetes mellitus (%) 30.77
† 18.52 26.67
|| 0
smoking (%) 41.03 29.63 50.00 25.6
obesity (%) 17.95* 3.70
¶ 26.67
|| 0
family history (%) 51.28* 48.15 26.67 22
physical inactivity (%) 92.31* 100.00
‡ 96.67
§ 39.5
*p < 0.05 STEMI vs controls; 
†p < 0.001 STEMI vs  controls; 
‡p < 0.001 NSAP vs controls; 
§p < 0.001 SAP vs controls; 
||p < 0.05 SAP vs con-
trols; 
¶p < 0.05 NSAP vs SAP
STEMI – ST elevation myocardial infarction; NSAP – non-stable angina pectoris; SAP – stable angina pectoris
Fig. 1 – Serum Fas/APO-1 (ng/mL) values in patients with ischemic heart disease
SAP – stable angina pectoris; NSAP – non-stable angina pectoris; AIM – acute myocardial infarction
Fig. 2 – Serum FasL (ng/mL) values in patients with ischemic heart disease
SAP – stable angina pectoris; NSAP – non-stable angina pectoris; AIM – acute myocardial infarctionStrana 540 VOJNOSANITETSKI PREGLED Volumen 67, Broj 7
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patients (6.981  ±  2.689 ng/mL) were significantly higher
than Fas levels in the controls (5.092  ±  1.252 ng/mL,
p < 0.01), but not significantly higher than Fas values in the
SAP (5.952  ±  2.069 ng/mL) and NSAP patients
(5.627  ±  2.270 ng/mL). Levels of FasL did not show any
significant difference among the studied groups.
The correlation between apoptotic markers, Fas/Apo1
and FasL, and inflammatory and lipid markers was studied
for each patient group. The significant correlation was ob-
served only in the SAP patients. Fas/APO1 showed a signifi-
cant positive correlation with the high sensitivity C-reactive
protein (hsCRP) (p < 0.05) (Figure 3) and a negative corre-
lation with high-density lipoprotein cholesterol (HDL-C)
(p < 0.05) (Figure 4), while FasL showed a significant posi-
tive correlation with low-density lipoprotein cholesterol
(LDL-C) (p < 0.05) (Figure 5).
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Fig. 3 – Correlation between Fas/APO-1 and high sensitivity
C-reactive protein (hsCRP) in stable angina pectoris patients
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Fig. 4 – Correlation between Fas/APO-1 and high-density
lipoprotein cholesterol (HDC-cholesterol) in stable angina
pectoris group
All patient groups were divided into two subgroups by
cholesterol levels (cholesterol levels in reference ranges 3.5–
5.5 mmol/L (Cholesterol -) and cholesterol levels higher than
reference values (Cholesterol +). Fas levels between these
subgroups showed a significant difference (p < 0.05) only in
NSAP patients (Table 2). In this group 51.85% of patients
had hypercholesterolemia.
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Fig. 5 – Correlation between FasL and low-density
lipoprotein cholesterol (LDL-cholesterol) in stable angina
pestoris group
Table 2
Cholesterol levels and Fas levels in non-stable angina pecto-
ris (NSAP) patients
NSAP patients Fas ( ng/mL) p
Cholesterol + 4.793 ± 1.449
Cholesterol - 7.243 ± 2.780
< 0.05
Cholesterol + – patients with cholesterol levels above 5.5 mmol/L;
cholesterol - – patients with cholesterol levels between 3.5 and 5.5 mmol/L
There are two subgroups in the SAP patient group ac-
cording to hsCRP levels (hsCRP levels lower than 3.0 mg/L
(hsCRP -), and hsCRP levels higher than 3.0 mg/L
(hsCRP+). Fas and FasL levels between these subgroups
showed a significant difference (p < 0.001, p < 0.05, respec-
tively) (Table 3).
Table 3
High sensitivity C-reactive protein (hsCRP) levels and
Fas/FasL levels in stable angina pectoris (SAP) patients
SAP patients Fas/FasL (ng/mL) p
hsCRP + Fas -5.74 ± 2.16 < 0.001
hsCRP - Fas -5.71 ± 2.04
hsCRP + FasL -0.075 ± 0.001 < 0.05
hsCRP - FasL -0.089 ± 0.017
hsCRP+ – patients with hsCRP levels higher than 3.0 ng/mL; hsCRp- – pati-
ents with hsCRP levels lower than 3.0 ng/mL
A strong correlations between Fas concentration and
diabetes mellitus (p < 0.05),  and  FasL  concentrations  and
both cholesterol (p  <  0.01) and triglycerides (p < 0.01)  in
NSAP patients were observed. The SAP patients  showed no
strong correlation between Fas and FasL concentration and
risk factors (Table 4).Volumen 67, Broj 7 VOJNOSANITETSKI PREGLED Strana 541
Ristić T, et al. Vojnosanit Pregl 2010; 67(7): 537–542.
Discussion
This study shows that sFas levels are significantly in-
creased only in STEMI patients compared to the controls
while sFas levels in other patient groups are not significantly
changed. Furthermore, sFasL levels were not significantly
different among the studied groups. The results obtained
from other studies in ischemic heart disease showed that sFas
levels are increased and sFasL levels are decreased in sub-
jects at high cardiovascular risk compared to healthy sub-
jects. Several single-center studies demonstrated that sFas
was elevated in patients with myocarditis, chronic congestive
heart failure and coronary artery disease, suggesting that the
Fas/FasL system may contribute to the pathogenesis of car-
diovascular disease 
12–14.
The Fas antigen is expressed on T and B cells, granylo-
cytes, monocytes, and natural killer cells, particularly on ac-
tivated cells. The Fas is cleaved by proteolytic enzymes pro-
duced by inflammatory cells and sFas is generated by alter-
native mRNA splicing 
15. The supernatants containing sFas
can inhibit auto-Fas-antibody induced apoptosis, hence indi-
cating that sFas may block signal transduction and apoptosis.
Overexpression of sFas protects the integrity of the vessel
wall from immune injury and attenuates transplant arterio-
sclerosis. The Fas is a novel and independent predictor of
active atherosclerotic disease in patients with end-stage renal
disease 
2. Our results showed a significant increase in serum
sFas only in STEMI patients. This findings may be explianed
by sFas proteolytic release from necrotic cardiomyocytes.
Serum Fas concentration increases in direct relation to the
severity of hemodynamic impairment in 17 patients with
AMI, but independently of the size of infarction 
14. However,
that study did not examine whether the increase in circulat-
ing sFas was a result of its releasing from cardiac tissue. An-
other study showed that the sFas concentration in the coro-
nary sinus was higher than in peripheral blood in the acute
phase of myocardial infarction, indicating that sFas found in
serum is secreted primarily from the heart in patients with
AIM 
16.
FasL is expressed on activated T cells, natural killer
cells and vascular endothelial cells. Since FasL is cleaved
from the cell membrane by a metalloproteinase-like en-
zyme
17 sFasL may be detected in the serum and considered
to be a marker of atherosclerosis. Data from a large-
population study showed that subjects at high cardiovascular
risk have markedly lower sFasL concentration than healthy
subjects and sFasL may be a novel marker of vascular injury
possibly related to endothelial function. For the first time,
sFasL levels in the circulation were elevated in the early phase
in patients with AMI and NSAP compared to the control sub-
jects. The mechanism by which plasma sFasL levels are ele-
vated in these patients is not clear at present. The finding that
sFasL levels were significantly higher in the coronary sinus
than in the peripheral vein suggests that sFasL may play role
as a local cytokine in culprit lesions and sFasL can induce a
proinflammatory effect. Hypoxia can stimulate the release of
sFasL from mononuclear cells accumulated in unstable plaque
which may serve as a source of sFasL in patients with AMI 
18.
Contrary to these findings, we did not observe any significant
difference in sFasL levels in any patient group. Similar results
were shown in patients with AMI on admission 
14.
Inflammation plays a role in all stages of atherogenesis
and some inflammatory markers, such as hsCRP, have been
shown to be independent predictors of coronary heart dis-
ease. It is well known that CRP is a marker of systemic in-
flammation and may contribute actively to the development
of the atherosclerotic lesions. Accumulation of CRP in early
atherosclerotic lesions may precede the appearance of mono-
cytes and native LDL co-incubated with CRP are taken up by
macrophages. Likewise, CRP induces adhesion molecule ex-
pression (ICAM-1, VCAM-1, E-selectin) by human umbili-
cal vein and coronary artery endothelial cells and can induce
the production of the chemokine MCP-1, too. Statins can
mediate this effect by inhibiting chemokine expression and
reducing CRP plasma levels 
19.
In our study sFas levels showed a positive correlation
with hsCRP levels and a negative correlation with HDL-C
levels in SAP patients. A positive correlation between FasL
levels and LDL-C levels was also observed. Contrary to
these findings, other authors showed that circulating sFas
concentrations did not correlate with any lipid parameter
analyzed at baseline, and the reduction observed in lipid val-
ues after atorvastatin treatment was not related to the change
in sFas concentrations 
20.
Table 4
Correlation between Fas/FasL and coronary risk factors
Non-stable angina pectoris Stable angina pectoris Risk factor Fas p FasL p Fas p FasL p
Cholesterol - 6.18 ± 1.39 0.10 ± 0.01 7.70 ± 3.41 0.08 ± 0.01
Cholesterol + 5.26 ± 2.53 0.07 ± 0.01 < 0.01 6.21 ± 1.48 0.07 ± 0.01
TG - 6.18 ± 1.39 0.10 ± 0.01 7.70 ± 3.42 0.08 ± 0.01
TG + 5.26 ± 2.53 0.07 ± 0.01 < 0.01 6.21 ± 1.48 0.07 ± 0.01
DM - 6.08 ± 1.95 0.09 ± 0.02 7.50 ± 2.99 0.08 ± 0.01
DM + 3.55 ± 0.23 < 0.05 0.06 ± 0.01 5.97 ± 2.01 0.07 ± 0.01
Smoking - 5.83 ± 2.14 0.08 ± 0.02 7.68 ± 3.42 0.07 ± 0.01
Smoking + 5.06 ± 1.31 0.08 ± 0.02 6.24 ± 1.52 0.08 ± 0.02
Family history - 5.66 ± 2.29 0.08 ± 0.02 8.81 ± 1.63 0.08 ± 0.01
Family history + 5.81 ± 1.81 0.09 ± 0.02 4.74 ± 1.86 0.08 ± 0.01
Obesity - 5.72 ± 2.02 0.08 ± 0.02 6.72 ± 3.42 0.08 ± 0.01
Obesity + – – 7.32 ± 2.53 0.07 ± 0.01
 TG – triglycedrides; DM – diabetes mellitusStrana 542 VOJNOSANITETSKI PREGLED Volumen 67, Broj 7
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There is evidence that Fas/FasL interactions may be re-
lated to augmented proliferation and inflammatory response. In
this sense, signals initiated by regulated Fas-associated death
domain protein overexpression induce expression of monocyte-
chemoattractant protein-1 and interleukin 8, and cause massive
migration of macrophages in vivo, indicating that Fas and FasL
act also as proinflammatory proteins. Univariate analyses dem-
onstrated that circulating sFas levels are increased in patients
with hypertension, diabetes or the metabolic syndrome com-
pared with patients without these pathologies 
20. Cigarette
smoke is an important source of oxidants, including H2O2, and is
thought to be a significant risk factor for chronic endothelial
damage leading to atherosclerosis 
21. Patients with familiar
combined hyperlipidemia or carotid atherosclerosis have de-
creased serum sFasL levels suggesting endothelial dysfunction
that may allow leukocyte infiltration of the vessel wall and lead
to atherosclerotic plaque formation 
22.
Our findings could be of pathophysiological impor-
tance, showing that there is an interdependence between in-
flammation and apoptosis in atherosclerotic blood vessels.
Expression of FasL itself by endothelial cells is related to
negative regulation of inflammation. It is possible that en-
dothelial dysfunction leads to reduced FasL synthesis and its
release into the blood. In our study plasma sFasL levels are
higher, but not significantly, in STEMI patients compared to
the other groups.
Conclusion
Our results showed that apoptotic process is disregu-
lated in patients with ischemic heart disease. There are Fas
and FasL interdependence with inflammatory and lipid
markers as well as with cardiovascular risk factors.
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